Equities research analysts expect that NewLink Genetics Corp (NASDAQ:NLNK) will post $5.78 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for NewLink Genetics’ earnings. The lowest sales estimate is $5.00 million and the highest is $7.35 million. NewLink Genetics reported sales of $2.76 million in the same quarter last year, which indicates a positive year over year growth rate of 109.4%. The firm is scheduled to announce its next quarterly earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that NewLink Genetics will report full year sales of $19.37 million for the current financial year, with estimates ranging from $18.10 million to $20.00 million. For the next fiscal year, analysts expect that the business will report sales of $11.37 million per share, with estimates ranging from $1.10 million to $20.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow NewLink Genetics.
NewLink Genetics (NASDAQ:NLNK) last released its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.69) by $0.32. NewLink Genetics had a negative return on equity of 60.60% and a negative net margin of 250.60%. The business had revenue of $10.10 million for the quarter, compared to the consensus estimate of $2.72 million.
A number of analysts have issued reports on NLNK shares. Zacks Investment Research raised NewLink Genetics from a “hold” rating to a “buy” rating and set a $9.00 price objective on the stock in a research note on Wednesday, January 3rd. BidaskClub raised NewLink Genetics from a “sell” rating to a “hold” rating in a research note on Friday, January 5th. Cantor Fitzgerald set a $26.00 price objective on NewLink Genetics and gave the stock a “buy” rating in a research note on Monday, January 8th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $21.00 price objective (down previously from $25.00) on shares of NewLink Genetics in a research note on Friday, March 2nd. Finally, Bank of America reduced their price objective on NewLink Genetics from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, March 2nd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the company. NewLink Genetics has an average rating of “Hold” and an average target price of $12.86.
NASDAQ:NLNK opened at $4.13 on Tuesday. NewLink Genetics has a 1 year low of $3.75 and a 1 year high of $20.47. The company has a market capitalization of $166.09, a price-to-earnings ratio of -1.79 and a beta of 1.22.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Redmile Group LLC increased its position in shares of NewLink Genetics by 67.9% during the 4th quarter. Redmile Group LLC now owns 2,096,490 shares of the biotechnology company’s stock valued at $17,003,000 after purchasing an additional 847,790 shares during the last quarter. Vident Investment Advisory LLC bought a new position in shares of NewLink Genetics during the 4th quarter valued at approximately $1,221,000. Millennium Management LLC increased its position in shares of NewLink Genetics by 56.6% during the 4th quarter. Millennium Management LLC now owns 2,347,359 shares of the biotechnology company’s stock valued at $19,037,000 after purchasing an additional 848,752 shares during the last quarter. Teachers Advisors LLC increased its position in shares of NewLink Genetics by 79.8% during the 4th quarter. Teachers Advisors LLC now owns 133,355 shares of the biotechnology company’s stock valued at $1,082,000 after purchasing an additional 59,201 shares during the last quarter. Finally, Raymond James & Associates bought a new position in shares of NewLink Genetics during the 4th quarter valued at approximately $240,000. 65.05% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/04/17/newlink-genetics-corp-nlnk-expected-to-post-quarterly-sales-of-5-78-million.html.
NewLink Genetics Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Get a free copy of the Zacks research report on NewLink Genetics (NLNK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.